Skip to main content
Log in

Valganciclovir

Cymeval, RO 1079070/194, RS 079070194, RS 79070

  • Section 1: Cytomegalovirus Retiniti
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Pescovitz MD, Rabkin J, Merion R, et al. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients. Transplantation 1999 Apr 15; 67: S126

    Article  Google Scholar 

  2. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999 Aug; 37: 167–76

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valganciclovir. Drugs R&D 2, 318–319 (1999). https://doi.org/10.2165/00126839-199902050-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00009

Keywords

Navigation